SavedAdd your journal

Journals / Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi / 2006 / Cilt: 3 - Sayı: 1

Peri ve postmenopozal dönemde farklı HT rejimlerinin serum homosistein düzeyleri üzerine etkileri

Effects of hormone therapy on serum homocysteine levels in peri-and postmenopausal women

Hakan KIRAN
GÜRKAN KIRAN
Turan ÇETİN
Pages
46–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall subjective cure rate was 90,85% for patients with stress urinary incontinence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To report our experience with tension-free vaginal tape (TVT) operation in patients with stress urinary incontinence and to assess the rate of success and complications associated with this procedure.
📊
Key Findings & Data:METHODS: We performed a retrospective review of 153 patients undergoing the TVT procedure in a 4 years period to report intraoperative and postoperative complications and success rate.
💡
Conclusion & Impact:The overall subjective cure rate was 90,85% for patients with stress urinary incontinence.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:İleriye dönük çalışma · Östrojenler · Postmenopoz

Abstract

OBJECTIVE: To report our experience with tension-free vaginal tape (TVT) operation in patients with stress urinary incontinence and to assess the rate of success and complications associated with this procedure. METHODS: We performed a retrospective review of 153 patients undergoing the TVT procedure in a 4 years period to report intraoperative and postoperative complications and success rate. RESULTS: Intraoperative complications only included 11 (7,20%) bladder perforations. Postoperative complications included 16 (10,46%) short term voiding dysfunction, 14 (9,15%) overactive bladder. The rate of bladder perforation was significantly higher in patients with previous antiincontinence surgery than in those without previous antiincontinence surgery, (13,46% (7/52) compared with 4,0% (4/101), p<0,05). Women with previous antiincontinence surgery had significantly higher short term voiding dysfunction rate than those who did not have any previous antiincontinence surgery, (21,15% (11/52) compared with 5,0% (5/101), p<0,05). The rate of overactive bladder was similiar in women with or without previous antiincontinence surgery, (9,61% (5/52) compared with 8,91% (9/101), p>0,05). The overall subjective cure rate was 90,85% for patients with stress urinary incontinence. CONCLUSIONS: The TVT is an efficacious procedure for the treatment of stress urinary incontinence and a safe procedure with an acceptable complication rate.

Özet

AMAÇ: Bu çalışmada kliniğimizde uyguladığımız Tension-free Tape operasyonunun stres üriner inkontinaslı vakalardaki etkinliğini ve komplikasyon oranlarını belirtmeyi amaçladık. METOD: Retrospektif olarak 4 yıllık süre içerinde kliniğimizde 153 hastaya uyguladığımız TVT operasyonun intraoperatif ve postoperatif komplikasyonlarını ve başarı oranınını inceledik. SONUÇLAR: İntraoperatif dönemde sadece 11 mesane perforasyonu gözlenmiştir (%7.20). Postoperatif dönemde 16 hastada kısa süreli işeme sorunları (%10,46) ve 14 hastada overaktif mesane (%9,15) izlenmiştir. Mesane perforasyon oranı daha önceden başka bir inkontinans cerrahisi geçirenlerde (%13,4; 7/52) geçirmeyenlere göre anlamlı olarak yüksek bulunmuştur (%4,0; 4/101) (p 0,05). Tüm hastalarda sübjektif kür oranı %90,85 bulunmuştur YORUM: TVT stres üriner inkontinanslı hastalarda etkili ve kabul edilebilir komplikasyon oranlarıyla beraber güvenli bir operasyondur.

🔖

Cite This Article

KIRAN, H., KIRAN, G., ÇETİN, T. (2006). Peri ve postmenopozal dönemde farklı HT rejimlerinin serum homosistein düzeyleri üzerine etkileri. Uzmanlık Sonrası Eğitim ve Güncel Gelişmeler Dergisi, Cilt: 3 - Sayı: 1, 46–50. https://ajindex.com/articles/320564

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RB, ed. Atherosclerotic cardiovascular disease, hemostasis and endothelial function. New York: Marcel Dekker, 1992; 183- 236
  2. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268(7): 877- 81
  3. McCully KS. Homocysteine and vascular disease. Nat Med.1996; 2(4): 386- 9
  4. Moustapha A. and Robinson K. Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics 1999; 54: 49-63
  5. Berger PB, Herrmann RR, Dumesic DA. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc. 2000; 75(1): 18-23
  6. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704- 9
  7. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230- 6
  8. Dallongeville J, Marecaux N, Isorez D, Zylberberg G, Fruchart J-C, Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995; 118: 123- 33
  9. Brattström LE, Hultberg BL, Hardebo JE. Folic acid responsive postmenopausal homocysteinemia. Metabolism 1985; 34: 63-67
  10. Pines A, Mijatovic V, van der Mooren MJ, Kenemans P. Hormone replacement therapy and cardioprotection:Basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol 1997; 71: 193- 7
  11. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991; 325: 756- 62
  12. Ridker P, Hennekens C, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836- 43
  13. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7): 605- 13
  14. Reed T, Malinow MR, Christian JC, Upson B